CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Average Price Target from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned an average recommendation of "Hold" from the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $73.11.

Several equities research analysts have recently weighed in on CRSP shares. Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. The Goldman Sachs Group lowered their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Bank of America decreased their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, Stifel Nicolaus dropped their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research report on Thursday, February 13th.

CRISPR Therapeutics Price Performance

CRSP traded up $5.04 on Monday, reaching $39.30. The company's stock had a trading volume of 3,645,107 shares, compared to its average volume of 1,622,765. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $67.88. The business's 50 day moving average is $41.14 and its 200 day moving average is $44.03. The stock has a market cap of $3.37 billion, a price-to-earnings ratio of -8.99 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, research analysts forecast that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its position in shares of CRISPR Therapeutics by 1.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after purchasing an additional 231 shares during the period. Captrust Financial Advisors grew its holdings in CRISPR Therapeutics by 32.0% during the third quarter. Captrust Financial Advisors now owns 31,712 shares of the company's stock worth $1,490,000 after acquiring an additional 7,688 shares during the period. State Street Corp raised its position in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares in the last quarter. XTX Topco Ltd lifted its holdings in CRISPR Therapeutics by 294.0% in the 3rd quarter. XTX Topco Ltd now owns 30,022 shares of the company's stock valued at $1,410,000 after acquiring an additional 22,402 shares during the last quarter. Finally, Main Management ETF Advisors LLC bought a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $693,000. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.